HUP0300335A2 - 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények - Google Patents

8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0300335A2
HUP0300335A2 HU0300335A HUP0300335A HUP0300335A2 HU P0300335 A2 HUP0300335 A2 HU P0300335A2 HU 0300335 A HU0300335 A HU 0300335A HU P0300335 A HUP0300335 A HU P0300335A HU P0300335 A2 HUP0300335 A2 HU P0300335A2
Authority
HU
Hungary
Prior art keywords
compounds
betha
hydrocarbyl
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0300335A
Other languages
English (en)
Inventor
Walter Elger
Karl-Heinrich Fritzemeier
Christa Hegele-Hartung
Alexander Hillisch
Uwe Kollenkirchen
Vladimir Patchev
Olaf Peters
Ina Thieme
Original Assignee
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10019167A external-priority patent/DE10019167A1/de
Application filed by Schering Ag. filed Critical Schering Ag.
Publication of HUP0300335A2 publication Critical patent/HUP0300335A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic

Abstract

A találmány új, (I) általános képletű 8b-szubsztituált ösztratriénekrevonatkozik, mely képletben R2, R3, R6, R6', R7, R7', R9, R11, R11',R12, R14, R15, R15', R16, R16', R17 és R17' jelentése a leírásbanmegadott és R8 egyenes vagy elágazó láncú, adott esetben részlegesenvagy teljesen halogénezett 1-5 szénatomos alkil- vagy 2-5 szénatomosalkenilcsoportot, etinil- vagy prop-l-inil-csoportot jelent. Ezek avegyületek felhasználhatók gyógyászati hatóanyagokként, amelyek invitro patkányprosztata ösztrogénreceptor-preparátumokon magasabbaffinitást mutatnak, mint patkányuterusz ösztrogénreceptor-preparátumokon és amelyek in vivo előnyösen inkább a csontokon hatnak,mint az uteruszon és/vagy kifejezett hatásuk az 5HT2a-receptor és -transzporter expressziójának stimulálását tekintve. A találmánytovábbá az új vegyületek terápiás alkalmazására és ezeket avegyületeket tartalmazó gyógyszerkészítményekre is vonatkozik. Ó
HU0300335A 2000-04-12 2001-04-12 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények HUP0300335A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10019167A DE10019167A1 (de) 2000-04-12 2000-04-12 Substituierte Estratriene als selektiv wirksame Estrogene
US20737000P 2000-05-26 2000-05-26
PCT/EP2001/004290 WO2001077139A1 (de) 2000-04-12 2001-04-12 8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene

Publications (1)

Publication Number Publication Date
HUP0300335A2 true HUP0300335A2 (hu) 2003-07-28

Family

ID=26005365

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300335A HUP0300335A2 (hu) 2000-04-12 2001-04-12 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Country Status (26)

Country Link
US (3) US7378404B2 (hu)
EP (2) EP1272505B1 (hu)
JP (2) JP3828423B2 (hu)
CN (1) CN100453549C (hu)
AT (2) ATE363487T1 (hu)
AU (3) AU2001273945A1 (hu)
BG (1) BG107173A (hu)
BR (1) BR0109983A (hu)
CA (1) CA2406177C (hu)
CZ (1) CZ20023382A3 (hu)
DE (1) DE50112561D1 (hu)
DK (2) DK1272504T3 (hu)
EA (1) EA006299B1 (hu)
EE (1) EE200200589A (hu)
ES (2) ES2287127T3 (hu)
HK (1) HK1057219A1 (hu)
HR (1) HRP20020892B1 (hu)
HU (1) HUP0300335A2 (hu)
IL (2) IL152248A0 (hu)
MX (1) MXPA02010066A (hu)
NO (2) NO325337B1 (hu)
NZ (1) NZ543724A (hu)
PL (1) PL207488B1 (hu)
PT (1) PT1272504E (hu)
SK (1) SK14632002A3 (hu)
WO (2) WO2001077139A1 (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1272504T3 (da) * 2000-04-12 2007-10-01 Bayer Schering Pharma Ag 8.Beta-hydrocarbylsubstituerede östradiener til anvendelse som selektive östrogener
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE10039199A1 (de) * 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
GB0020498D0 (en) * 2000-08-18 2000-10-11 Sterix Ltd Compound
DE10151363A1 (de) * 2001-10-17 2003-05-08 Schering Ag Somatotrope Therapie
DE10226326A1 (de) * 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
EP1468690B1 (en) * 2003-03-27 2008-10-08 Pantarhei Bioscience B.V. Use of estrogens for the treatment of infertility in male mammals
DE10318896A1 (de) * 2003-04-22 2004-11-25 Schering Ag 8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene
PT1689410E (pt) * 2003-11-26 2008-08-18 Bayer Schering Pharma Ag Prevenção e tratamento de doenças cardíacas hipertensivas pelos estrogénios selectivos 8beta-vinil-estra-1,3,5(10)-trieno-3,17beta-diol e 17beta-fluoro-9alfa-vinil-estra-1,3,5(10)-trieno-3,16alfa-diol
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057225A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP2014672A1 (en) * 2007-07-12 2009-01-14 Bayer Schering Pharma Aktiengesellschaft 8-beta-substituted estratrienes as selectively active estrogens
CA2714340A1 (en) * 2008-02-13 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
WO2009100871A2 (en) * 2008-02-13 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Drug delivery system with stabilising effect
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
EP2358351A1 (en) * 2008-11-21 2011-08-24 Bayer Pharma Aktiengesellschaft Drug delivery system
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2743E (fr) * 1902-01-11 1904-12-15 Adolphe Ernest Pointe Panification augmentant le rendement et la digestibilité
JPS454059Y1 (hu) * 1967-11-04 1970-02-25
JPS454060Y1 (hu) * 1967-12-11 1970-02-25
US3501530A (en) * 1968-02-27 1970-03-17 American Cyanamid Co Substituted naphthalenones,naphthalenediones and d-homo - beta - nor estra-1,3,5(10),9(11)-tetraenes
US3681407A (en) * 1969-06-18 1972-08-01 American Cyanamid Co 3-methoxy 8{62 -methylestra 1,3,5(10),9(11)-tetraene-17{62 -carboxylic acid lower alkyl ester and intermediates in the preparation thereof
US3806546A (en) * 1969-06-18 1974-04-23 American Cyanamid Co Steroid-like compounds and method of synthesis
US3709878A (en) * 1970-07-20 1973-01-09 Sandoz Ag 8 alpha-methyl-substituted-steroids
US3736345A (en) * 1971-05-18 1973-05-29 American Cyanamid Co Steroid-like compounds and method of synthesis
US4961931A (en) * 1982-07-29 1990-10-09 Alza Corporation Method for the management of hyperplasia
DE4018828C2 (de) * 1989-06-08 1999-05-12 Schering Ag Verfahren zur Herstellung C7-alpha-substituierter 8alpha- und 8ß-Estra-1,3,5(10)-triene und C8-alpha-substituierter Estra-1,3,5(10)-triene sowie neue Zwischenprodukte für dieses Verfahren
ATE194358T1 (de) * 1996-05-01 2000-07-15 Us Gov Health & Human Serv 21-substituierte progesteron derivate als antigestagene
ATE222922T1 (de) * 1998-11-20 2002-09-15 Akzo Nobel Nv Estrogenische estra-1,3,5(10)-trien verbindungen mit verschiedenen wirkungen auf estrogenrezeptor alpha und beta mit einer unverzweigten kohlenwasserstoffkette von 5-9 kohlenstoffatomen in position 11
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene
DK1272504T3 (da) * 2000-04-12 2007-10-01 Bayer Schering Pharma Ag 8.Beta-hydrocarbylsubstituerede östradiener til anvendelse som selektive östrogener
DE10318896A1 (de) * 2003-04-22 2004-11-25 Schering Ag 8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene

Also Published As

Publication number Publication date
JP2008280355A (ja) 2008-11-20
EP1272505B1 (de) 2005-08-24
MXPA02010066A (es) 2003-06-04
EA006299B1 (ru) 2005-10-27
CA2406177A1 (en) 2001-10-18
PL358667A1 (en) 2004-08-09
EP1272504B1 (de) 2007-05-30
NO20024907L (no) 2002-12-05
US7378404B2 (en) 2008-05-27
BR0109983A (pt) 2003-02-25
AU5834101A (en) 2001-10-23
NO20024908D0 (no) 2002-10-11
HRP20020892A2 (en) 2005-02-28
JP2003530403A (ja) 2003-10-14
IL152248A (en) 2008-06-05
CN1433424A (zh) 2003-07-30
BG107173A (bg) 2003-05-30
ES2245694T3 (es) 2006-01-16
IL152248A0 (en) 2003-05-29
CN100453549C (zh) 2009-01-21
DE50112561D1 (de) 2007-07-12
ES2287127T3 (es) 2007-12-16
PT1272504E (pt) 2007-08-29
PL207488B1 (pl) 2010-12-31
HK1057219A1 (en) 2004-03-19
NO325337B1 (no) 2008-03-31
EA200201052A1 (ru) 2003-04-24
EP1272504A1 (de) 2003-01-08
HRP20020892B1 (en) 2011-08-31
NZ543724A (en) 2007-07-27
DK1272505T3 (da) 2005-11-07
NO20024908L (no) 2002-11-13
NO20024907D0 (no) 2002-10-11
ATE302790T1 (de) 2005-09-15
DK1272504T3 (da) 2007-10-01
AU2001273945A1 (en) 2001-10-23
US20030176405A1 (en) 2003-09-18
CZ20023382A3 (cs) 2003-02-12
ATE363487T1 (de) 2007-06-15
EE200200589A (et) 2004-04-15
US20080182829A1 (en) 2008-07-31
CA2406177C (en) 2010-06-22
AU2001258341B2 (en) 2007-03-15
JP3828423B2 (ja) 2006-10-04
US20040029847A1 (en) 2004-02-12
WO2001077138A1 (de) 2001-10-18
EP1272505A1 (de) 2003-01-08
WO2001077139A1 (de) 2001-10-18
SK14632002A3 (sk) 2003-03-04

Similar Documents

Publication Publication Date Title
HUP0300335A2 (hu) 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
PE20051038A1 (es) Uso extendido de combinacion que comprende estrogenos y progestinas
ITMI961152A1 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
EA201201221A1 (ru) Фармацевтическая композиция для контрацепции и заместительной гормональной терапии
TR200100234T2 (tr) Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması.
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
ES2299730T3 (es) Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer.
EA200100828A1 (ru) 16-гидроксиэстратриены в качестве эстрогенов избирательного действия
ECSP055530A (es) Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva
HUP0105134A2 (hu) Szubsztituált 2-arilimino-heterociklusok és ilyen vegyületeket tartalmazó készítmények progeszteron receptorhoz kötődő szerekként való alkalmazásra
DK1226155T3 (da) 18-nor-steroider som selektivt virksomme östrogener
YU77302A (sh) 8beta-hidrokarbil-supstituisani estratrieni kao selektivno delotvorni estrogeni
TR200301552A1 (tr) Rofekoksib' in yeni oral farmakolojik formülasyonları.
TR200003857T2 (tr) 17 Konumunda halojenlenmiş yeni 19-nor steroitler.
BR0010070A (pt) Uso de org 33245, kit contraceptivo, meio combinado para a dosagem de um progestogênio e um antiprogestogênio, e, métodos de contracepção, e de tratamento de sangramento uterino irregular ou de ruptura em uma fêmea utilizando uma preparação somente de progestogênio
PL352029A1 (en) 14-beta-h-sterols, pharmaceutical compositions containing these sterols and use of these derivatives for obtaining drugs to regulate meioses
UY26967A1 (es) Derivados 8beta-sustituidos de 11beta-pentil y 11beta-hexil-estra-1,3,5(10)-trieno.-

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees